Trends in hypersensitivity drug reactions: More drugs, more response patterns, more heterogeneity

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 3, 2014, Pages 143-153

  Dona I ^a   Barrionuevo, E ^a   Blanca Lopez, N ^b   Torres, M J ^a   Fernandez, T D ^c   Mayorga, C ^c   Canto, G ^b   Blanca, Miguel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c Research Laboratory of Allergy Diseases   (Spain)

Author keywords

Biological agents; Contrast media; Drug hypersensitivity; Mechanisms; NSAIDs; Quinolones; Trends; lactams

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ATRACURIUM BESILATE; CEPHALOSPORIN; CHIMERIC ANTIBODY; CIPROFLOXACIN; CISATRACURIUM; CYCLOOXYGENASE 1; IMMUNOGLOBULIN E; IODIXANOL; IOMEPROL; LEVOFLOXACIN; MONOCLONAL ANTIBODY; MOXIFLOXACIN; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PANCURONIUM; PENICILLIN G; POLYCLONAL ANTIBODY; PROPIONIC ACID; PYRAZOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADIOPHARMACEUTICAL AGENT; ROCURONIUM; SULFONAMIDE; SUXAMETHONIUM; UNINDEXED DRUG;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ACUTE HEART INFARCTION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRONCHUS OBSTRUCTION; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DYSPNEA; FIXED DRUG ERUPTION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; KIDNEY FAILURE; NEPHRITIS; NONHUMAN; NOSE OBSTRUCTION; REVIEW; RHINORRHEA; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ANTI-BACTERIAL AGENTS; BIOLOGICAL FACTORS; CONTRAST MEDIA; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; NEUROMUSCULAR BLOCKING AGENTS; T-LYMPHOCYTES;

EID: 84903379469     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. World Health Organization. International drug monitoring: the role of the hospital. Geneva: The Organization; 1966.
2. Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, editor. Textbook of adverse drug reactions. New York: Oxford University Press; 1991. p.18-45.
3. Borda I, Slone D, Jick H. Assessment of adverse reactions within a drug surveillance program. JAMA. 1968; 205: 645-7.
4. Coombs R, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell P, Coombs RR, Lachman PJ, editors. Clinical aspects of immunology. Oxford: Blackwell Scientific Publications; 1975. p.761.
5. Demoly P, Hillarie-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin N Am. 2004; 24: 345-6.
6. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113: 832-6.
7. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy ClinImmunol. 2005; 5: 309-16.
8. Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to Aspirin and Nonsteroidal Anti-Infl amatory Drugs. In: Adkinson, Busse, Bochner, Holgate, Simons, Lemanske, editors. Middleton's Allergy Principles and Practice. Philadelphia: Mosby; 2009. p. 1227-43.
9. Sánchez-Borges M. NSAID Hypersensitivity (Respiratory, Cutaneous, and Generalized Anaphylactic Symptoms). Med Clin N Am. 2010; 94: 853-64.
10. Gruchalla RS. Drug allergy. J Allergy ClinImmunol. 2003; 111 (2 Suppl) 2: S548-59.
11. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011; 71: 684-700.
12. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol. 2001; 1: 305-10.
13. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy. 2002; 57 Suppl 72: S37-40.
14. Adkinson NF Jr, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler JD, Updyke L, Shear NH, Wierda D; Health and Environmental Sciences Institute Task Force. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol. 2002; 109 Suppl (3): S461-78.
15. Mockenhaupt M. Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Pichler WJ, editor. Drug Hypersensitivity. Basel: Karger; 2007. p.18-31.
16. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol. 2007; 7: 299-303.
17. Bousquet PJ, Demoly P, Romano A, Aberer W, Bircher A, Blanca M, Brockow K, Pichler W, Torres MJ, Terreehorst I, Arnoux B, Atanaskovic-Markovic M, Barbaud A, Bijl A, Bonadonna P, Burney PG, Caimmi S, Canonica GW, Cernadas J, Dahlen B, Daures JP, Fernandez J, Gomes E, Gueant JL, Kowalski ML, Kvedariene V, Mertes PM, Martins P, Nizankowska-Mogilnicka E, Papadopoulos N, Ponvert C, Pirmohamed M, Ring J, Salapatas M, Sanz ML, Szczeklik A, Van Ganse E, De Weck AL, Zuberbier T, Merk HF, Sachs B, Sidoroff A; Global Allergy, Asthma European Network (GALEN) and Drug Allergy and Hypersensitivity Database (DAHD) and the European Network for Drug Allergy (ENDA). Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy. 2009; 64: 194-203.
18. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W, Brockow K, Pichler WJ, Demoly P; ENDA; EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy. 2003; 58: 961-72.
19. Gamboa PM. The epidemiology of drug allergyrelated consultations in Spanish Allergology Services: Alergológica-2005. J Investig Allergol Clin Immunol. 2009; 19 Suppl 2: 45-50.
20. Blanca M, Romano A, Torres MJ, Férnandez J, Mayorga C, Rodriguez J, Demoly P, Bousquet PJ, Merk HF, Sanz ML, Ott H, Atanaskovi-Markovi M. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy. 2009; 64: 183-93.
21. England RW, Ho TC, Napoli DC, Quinn JM. Inpatient consultation of allergy/immunology in a tertiary care setting. Ann Allergy Asthma Immunol. 2003; 90: 393-7.
22. Dietrich JJ, Quinn JM, England RW. Reasons for outpatient consultation in allergy/immunology. Allergy Asthma Proc. 2009; 30: 69-74.
23. Blanca M. Allergic reactions to penicillins. A changing world? Allergy. 1995; 50: 777-82.
24. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, Rosado A, Rondón C, Campo P, Agúndez JA, Blanca M, Canto G. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011; 41: 86-95.
25. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis and management. J Allergy Clin Immunol. 2003; 111: 913-21.
26. Levine BB, Ovary Z. Studies of the mechanism of the formation of the penicillin antigen. III. The N-(D-alphabenzylpenicilloyl) group as an antigenic determinant responsible for hypersensitivity to penicillin G. J Exp Med. 1961; 114: 875-904.
27. Dewdney JM. Immunology of the antibiotics. In: Sela M, editor, The antigens, vol. 4. New York: Academic Press; 1977. p. 114-22.
28. Naisbitt D, Williams D, Pirmohamed M, Kitteringham N, Park K. Reactive metabolites and their role in drug reactions. Curr Opin AllergyImmunol. 2001; 1: 317-25.
29. Doña I, Blanca-López N, Torres MJ, García-Campos J, García-Núñez I, Gómez F, Salas M, Rondón C, Canto MG, Blanca M. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012; 22: 363-71.
30. Antúnez C, Martín E, Cornejo-García JA, Blanca-Lopez N, R-Pena R, Mayorga C, Torres MJ, Blanca M. Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des 2006; 12: 33 27-33.
31. Castell JV, Castell M. Allergic hepatitis induced by drugs. Curr Opin Allergy Clin Immunol. 2006; 6: 258-65.
32. Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibotics. Clin Allergy. 1988; 18: 515-40.
33. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med. 2004; 140: 100 1-6.
34. Rebelo-Gomez, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005; 5: 309-16.
35. Torres MJ, Ariza A, Mayorga C, Doña I, Blanca-Lopez N, Rondon C, Blanca M. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol. 2010; 125: 502-5.
36. Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am. 2010; 94: 805-20.
37. Ponvert C, Perrin Y, Bados-Albiero A, Le Bourgeois M, Karila C, Delacourt C, Scheinmann P, De Blic J. Allergy to betalactam in children. Pediatr Allergy Immunol. 2011; 22: 411-8.
38. Torres MJ, Blanca M. The contribution of major and minor determinants from benzylpenicillin to the diagnosis of immediate allergy to beta-lactams. J Allergy Clin Immunol. 2006; 117: 220-1.
39. Torres MJ, Mayorga C, Blanca M. Nonimmediate Allergic Reactions Induced by Drugs: Pathogenesis and Diagnostic Tests. J Investig Allergol Clin Immunol. 2009; 19: 80-90.
40. Torres MJ, Padial A, Mayorga C, Fernández T, Sanchez-Sabate E, Cornejo-García JA, Antúnez C, Blanca M. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy. 2004; 34: 1768-75.
41. Blanca-López N, Ariza A, Doña I, Mayorga C, Montañez MI, Garcia-Campos J, Gomez F, Rondón C, Blanca M, Torres MJ. Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clin Exp Allergy. 2013; 43: 560-7.
42. Sachs B, Riegel S, Seebeck J, Beler R, Schichler D, Barger A, Merk HF, Erdmann S. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf. 2006; 29: 1087-100.
43. Aranda A, Mayorga C, Ariza A, Doña I, Rosado A, Blanca-Lopez N, Andreu I, Torres MJ. In vitro evaluation of IgEmediated hypersensitivity reactions to quinolones. Allergy. 2011; 66: 247-54.
44. Seitz CS, Bröcker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clin Exp Allergy. 2009; 39: 1738-45.
45. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and crossreactivity. Clin Exp Allergy. 2006; 36: 59-69.
46. Fernandez-Rivas M. Fixed drug eruption (FDE) caused by norfloxacin. Allergy. 1997; 52: 477-8.
47. Alonso MD, Martín JA, Quirce S, Dávila I. Fixed eruption caused by ciprofloxacin with cross-sensitivity to norfloxacin. Allergy. 1993; 48: 296-7.
48. Davila G, Ruiz-Hornillos J, Rojas P, De Castro F, Zubeldia JM. Toxic epidermal necrolysis induced by levofloxacin. Ann Allergy Asthma Immunol. 2009; 102: 441-2.
49. Yoon SY, Bae YJ, Cho YS, Moon HB, Kim TB. Toxic epidermal necrolysis induced by ofloxacin. Acta Derm Venereol. 2010; 90: 550-1
50. Islam AF, Rahman MS. Levofloxacin-induced fatal toxic epidermal necrolysis. Ann Pharmacother. 2005; 39: 1136-7.
51. Cuquerella MC, Miranda MA, Bosca F. Role of excited state intramolecular charge transfer in the photophysical properties of norfloxacin and its derivatives. J Phys Chem A. 2006; 110: 2607-12.
52. Blanca-López N, Andreu I, Torres Jaén MJ. Hypersensitivity reactions to quinolones. Curr Opin Allergy Clin Immunol. 2011; 11: 285-91.
53. Lobera T, Audícana MT, Alarcón E, Longo N, Navarro B, Muñoz D. Allergy to quinolones: low cross-reactivity to levofl oxacin. J Investig Allergol Clin Immunol. 2010; 20: 607-11.
54. Lazaro E, de abajo F. Uso de antibióticos en España. Spanish Agency for drugs, Pharmaco-epidemiology Division (AEMPS) Publication 2010; 1-9.
55. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol. 2003; 112: 629-30.
56. Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Curr Allergy Asthma Rep. 2005; 5: 15-21.
57. Manfredi M, Severino M, Testi S, Macchia D, Ermini G, Pichler WJ, Campi P. Detection of specific IgE to quinolones. J Allergy Clin Immunol. 2004; 113: 155-60.
58. Ben Said B, Berard F, Bienvenu J, Nicolas JF, Rozieres A. Usefulness of basophil activation tests for the diagnosis of IgE-mediated allergy to quinolones. Allergy. 2010; 65: 535-6.
59. Rouzaire P, Nosbaum A, Denis L, Bienvenu F, Bérard F, Cozon G, Bienvenu J. Negativity of the basophil activation test in quinolone hypersensitivity: a breakthrough for provocation test decision-making. Int Arch Allergy Immunol. 2012; 157: 299-302.
60. Gomez E, Blanca M, Torres MJ, Mayorga C. Immunologic evaluation of drug allergy. Allergy Asthma Immunol Res. 2012; 4: 251-63.
61. Mayorga C, Torres MJ, Fernandez J, Canto G, Blanca M. Cutaneous symptoms in drug allergy: what have we learnt? Curr Opin Allergy Clin Immunol. 2009; 9: 431-6.
62. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Neil Shear N, Schöpf E, Kaufman DW. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333: 1600-7.
63. Fernandez TD, Canto G, Blanca M. Molecular mechanisms of maculopapular exanthema. Curr Opin Infect Dis. 2009; 22: 272-8.
64. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, Pichler WJ, Demoly P; ENDA; EAACI. Diagnosis of nonimmediate reactions to betalactams antibiotics. Allergy. 2004; 59: 1153-60.
65. Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol. 2004; 16: 732-7.
66. Rzany B, Mockenhaupt M, Baur S, Schröder W, Stocker U, Mueller J, Holländer N, Bruppacher R, Schöpf E. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolisis in Germany (1990- 1992): structure and results of a population-based registry. J Clin Epidemiol. 1996; 49: 769-73.
67. Kamaliah MD, Zaimal D, Mokhtar N, Nazmi N. Erythema multiforme, Steven Johnson Syndrome and toxic epidermal necrolysis in North East Malaysia. Int J Dermatol. 1998; 37: 520-3.
68. Blanca-Lopez N, Zapatero L, Alonso E, Torres MJ, Fuentes V, Martinez-Molero MI, Blanca M. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy. 2009; 64: 229-33.
69. Brockow K, Christiansen C, Kanny G, Clement O, Barbaud A, Bircher A, Dewachter P, Guéant JL, Rodriguez Guéant RM, Mouton-Faivre C, Ring J, Romano A, Sainte-Laudy J, Demoly P, Pichler WJ; ENDA; EAACI interest group on drug hypersensitivity. Management of hypersensitivity reactions to iodinated contrast media. Allergy. 2005; 60: 150-8.
70. Gomez E, Ariza A, Blanca-Lopez N, Torres MJ. Non-immediate hypersensitivity reactions to contrast media. Curr Opin Allergy Clin Immunol. 2013; 13: 345-53.
71. Wolf GL, Arenson RL, Cross AP. A prospective trial of ionic vs non-ionic contrast agents in routine clinical practice: Comparison of adverse effects. Am J Roentgenol. 1989; 152: 939-44.
72. Palmer FJ. The RACR survey of intravenous contrast media reactions. Final report. Australas Radiol. 1988; 32: 426-8.
73. Ring J, Arroyave CM, Frizler MJ, Tan EM. In vitro histamine and serotonin release by radiographic contrast media (RCM). Complement-dependent and-independent release reaction and changes in ultrastructure of human blood cells. Clin Exp Immunol. 1978; 32: 105-18.
74. Stellato C, de Crescenzo G, Patella V, Mastronardi P, Mazzarella B, Marone G. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. J Allergy Clin Immunol. 1996; 97: 838-50.
75. Laroche D, Aimone-Gastin I, Dubois F, Huet H, Gerard P, Vergnaud M-C, Mouton-Faivre C, Guéant JL, Laxenaire MC, Bricard H. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology. 1998; 209: 183-90.
76. Bhananker SM, O'Donnell JT, Salemi JR, Bishop MJ. The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of food and drug administration reporting of adverse events. Anesth Analg. 2005; 101: 819-22.
77. Laxenaire MC. Drugs and other agents involved in anaphylactic shock occurring during anaesthesia. A French multicenter epidemiological inquiry. Ann Fr Anesth Reanim. 1993; 12: 91-6.
78. Mertes PM, Laxenaire MC. Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002). Ann Fr Anesth Reanim. 2004; 23: 1133-43.
79. Moneret-Vautrin DA, Widmer S, Gueant JL, Kamel L, Laxenaire MC, Mouton C, Gerard H. Simultaneous anaphylaxis to thiopentone and a neuromuscular blocker: a study of two cases. Br J Anaesth. 1990; 64: 743-5.
80. Sanchez-Guerrero IM, Tortosa JA, Hernandez-Palazon J, Escudero AI. Anaphylactoid reaction induced by pancuronium during general anaesthesia. Eur J Anaesthesiol. 1998; 15: 613-4.
81. Lagneau F, Corda B, Marty J. Possible underestimation of the relative incidence of anaphylactic reactions to benzylisoquinoline neuromuscular blocking agents. Eur J Anaesthesiol. 2003; 20: 577-8.
82. Laxenaire MC, Moneret-Vautrin DA. Anaphylactic reactions to rocuronium. Br J Anaesth. 2000; 85: 325-6.
83. Rose M, Fisher M. Rocuronium: high risk for anaphylaxis? Br J Anaesth. 2001; 86: 678-82.
84. Heier T, Guttormsen AB. Anaphylactic reactions during induction of anaesthesia using rocuronium for muscle relaxation: a report including 3 cases. Acta Anaesthesiol Scand. 2000; 44: 775-81.
85. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: a 6-year singlecenter follow-up study. Anesthesiology. 2005; 102: 897-903.
86. Mertes PM, Laxenaire MC, Alla F. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003; 99: 536-45.
87. Light KP, Lovell AT, Butt H, Fauvel NJ, Holdcroft A. Adverse effects of neuromuscular blocking agents based on yellow card reporting in the U.K.: are there differences between males and females? Pharmacoepidemiol Drug Saf. 2006; 15: 151-60.
88. Fisher M, Baldo BA. Anaphylaxis during anaesthesia: current aspects of diagnosis and prevention. Eur J Anaesthesiol. 1994; 11: 263-84.
89. Laxenaire MC, Gastin I, Moneret-Vautrin DA, Widmer S, Guéant JL. Cross-reactivity of rocuronium with other neuromuscular blocking agents. Eur J Anaesthesiol Suppl 1995; 11: 55-64.
90. Mertes PM, Guttormsen AB, Harboe T, Johansson SG, Florvaag E, Husum B, Garvey LH, Kroigaard M, Gramstad L, Kvande KT, Trechot P, Malinovsky JM. Can spontaneous adverse event reporting systems really be used to compare rates of adverse events between drugs? Anesth Analg. 2007; 104: 471-2.
91. Gueant JL, Gueant-Rodriguez RM, Cornejo-Garcia JA, Viola M, Blanca M, Romano A. Gene variants of IL13, IL4, and IL4RA are predictors of beta-lactam allergy. J Allergy Clin Immunol. 2009; 123: 509-10.
92. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sørensen R, Rasmussen JN, Køber L, Madsen M, Torp-Pedersen C. The pattern of use of non steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Safety. 2008; 17: 822-33.
93. Roberts LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LL, Goodman Gilman A, editors. The pharmacological basis of therapeutics, 10th edn. New York: McGraw-Hill; 2001. p.687-731.
94. Manfredi G. Adverse drug reactions prevalence in south Italy. Allergy. 2008; 63: S110-1.
95. Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy. 2004; 34: 1597-601.
96. Chen CJ, Cheng CF, Lin HY, Hung SP, Chen WC, Lin MS. A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. J Clin Pharm Ther. 2012; 37: 647-51.
97. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, Ebner H, Ebner C. IgE-mediated immediate type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol. 2003; 111: 882-8.
98. Schneider CH, Kasper MF, de Weck AL, Rolli H, Angst BD. Diagnosis of antibody-mediated drug allergy. Pyrazolinone and pyrazolidinedione cross-reactivity relationships. Allergy. 1987; 42: 597-603.
99. Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, Suau R. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy. 1989; 62: 295-298.
100. Canto MG, Andreu I, Fernandez J, Blanca M. Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol. 2009; 9: 293-7.
101. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, Brockow K, Campo P, Celik G, Cernadas J, Cortellini G, Gomes E, Nizankowska-Mogilnicka E, Romano A, Szczeklik A, Testi S, Torres MJ, Wöhrl S, Makowska J. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal antiinflammatory drugs. Allergy. 2013; 68(10): 1219-32.
102. Ayuso P, Cornejo-Garcia JA, Blanca-Lopez N, Doña I, Torres MJ, Gueant-Rodriguez R, Canto G, Sanak M, Mayorga C, Gueant JL, Blanca M. Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin Exp Allergy. 2013; 43(10): 1097-9.
103. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006; 118: 773-86.
104. Micheletto C, Visconti M, Tognella S, Facchini FM, Dal Negro RW. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. Eur Ann Allergy Clin Immunol. 2006; 38: 20-3.
105. Asero R. Intolerance to nonsteroidal antiinflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol. 2003; 111: 1095-8.
106. Asero R. Multiple nonsteroidal anti-inflammatory druginduced cutaneous disease: what differentiates patients with and without underlying chronic spontaneous urticaria? Int Arch Allergy Immunol. 2013; 163(2): 114-8.
107. Doña I, Blanca-López N, Torres MJ, Gómez F, Fernández J, Zambonino MA, Monteseirín FJ, Canto G, Blanca M, Cornejo-García JA. NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy. 2014; 69: 438-44.
108. Lafrance JP, Miller DR. Selective and non-selective nonsteroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf. 2009; 18: 923-31.
109. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, Sørensen R, Folke F, Buch P, Gadsbøll N, Rasmussen S, Poulsen HE, Køber L, Madsen M, Torp-Pedersen C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2009; 169(2): 141-9.
110. Nettis E, Giordano D, Colanardi MC, Paradiso MT, Ferrannini A, Tursi A. Delayed-type hypersensitivity rash from ibuprofen. Allergy. 2003; 58: 539-40.
111. Nassim A, Chernajovsky Y. Historical development of antibody therapies. In: Nassim A, Chernajovsky Y, editors. Therapeutic Antibodies. Berlin: Sprringer Verlag; 2010.
112. Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov. 2013; 12: 306-24.
113. Reichert JM. Antibodies to watch in 2013. Mid-year update. mAbs. 2013; 5: 513-17.
114. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008; 14: 154-69.
115. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature. 1984; 312: 643-6.
116. Hwang WY, Foote J. Immunogenicity of engineering antibodies. Methods. 2005; 36: 3-10.
117. Pichler JW. Adverse side-effects to biological agents. Allergy. 2006; 61: 912-20.
118. Badouin V et al. Anaphylactic shock caused by IgE sensitisation after treatment with the chimeric anti-IL2R mAb basiliximab. Transplantation. 2003; 15: 76.
119. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010; 65: 657-61
120. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA. Cetuximabinduced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008; 358: 1109-17.
121. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007; 120: 1373-7.
122. Cohen M, Rocher F, Vivinus S, Thomas P, Lebrun C. Giant urticaria and persistent neutralizing antibodies after the first natalizumab infusion. Neurology. 2010; 74: 1394-5.
123. Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS, Gaspari AA. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol. 2008; 144: 1190-4.
124. Bishara AI, Hagmeyer KO. Acute profound thrombocytopenia following abciximab therapy. Ann Pharmacother. 2000; 34: 924-30.
125. Kwan JM, Reese AM, Trafeli JP. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol. 2008; 58: 1053-5.
126. Ashraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab. Ann Pharmacother. 2009; 43: 383-6.
127. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006; 30: 41-4.
128. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol. 2007; 120: 972-3.
129. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn disease. World J Gastroenterol. 2009; 15: 4449-52.
130. Torres MJ, Chaves P, Doña I, Blanca-López N, Canto G, Mayorga C, Blanca M. T-cell involvement in delayed-type hypersensitivity reactions to infliximab. J Allergy Clin Immunol. 2011; 128: 1365-7.
131. Moneret-Vautrin DA, Morisset M, Vignaud JM, Kanny G. T cell mediated allergy to abciximab. Allergy. 2002; 57: 269-70.